Trametinib,a MEK inhibitor,overcomes resistance to EGFR-TKI in NSCLC

Kenji Takeuchi

[1P-314] Trametinib,a MEK inhibitor,overcomes resistance to EGFR-TKI in NSCLC

^〇Kenji Takeuchi¹, Yukito Seike¹, Saki Shimizu¹, Kazuto Tomimura¹, Ryuji Yamazawa¹, Kiyoshi Ito¹ (Fac. Pharm. Sci., Setsunan Univ.)

キーテクノロジー：Western blot法

非小細胞肺がん、EGFRチロシンキナーゼ阻害剤、JNK、Trametinib、Bim

takeuchi@pharm.setsunan.ac.jp

Contents of this site has moved to the member page of The Japanese Biochemical Society: https://member.jbsoc.or.jp/mypage/
You can access the abstracts without credentials by accessing them via the member page.

You need the membership number and password to access the member page. Please contact the journal office for any inquiries.

Journal Office Contact Information:
E-mail:jbs-ho@jbsoc.or.jp
Tel:03(3815)1913 Fax:03(3815)1934

The 96th Annual Meeting of the Japanese Biochemical Society

[1P-314] Trametinib,a MEK inhibitor,overcomes resistance to EGFR-TKI in NSCLC

Password